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Purpose: To evaluate the effect of intravitreal injection of a Rho-associated protein kinase 
(ROCK) inhibitor (Fasudil, Asahi Kasei Pharma Corporation, Tokyo, Japan) combined 
with intravitreal bevacizumab (IVB) on refractory diabetic macular edema (DME).
Methods: This prospective, interventional case series included 15 eyes of 15 patients 
with DME unresponsive to previous IVB injections. Eligible eyes underwent intravitreal 
injection of 0.025 mg Fasudil and 1.25 mg bevacizumab. Best corrected visual acuity 
(BCVA) and central macular thickness (CMT) were evaluated before and 4 weeks after 
treatment.
Results: Mean age was 64.6±7.3 (range, 49-79) years and mean number of previous 
IVB injections was 2.8. Mean pre-injection BCVA was 0.84±0.35 LogMAR, which was 
improved to 0.49±0.29 LogMAR four weeks after intervention (P=0.003). Mean CMT was 
decreased from 448±123 µm before treatment, to 347±76 µm at four weeks (P=0.001); 
no adverse event was observed during the study period. 
Conclusion: Intravitreal ROCK inhibitors seem to entail structural and visual benefits 
in eyes with DME refractory to IVB monotherapy. 
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INTRODUCTION
Non-proliferative diabetic retinopathy is 
characterized by retinal microvascular damage, 
leading to vascular hyper-permeability and 
diabetic macular edema (DME). Many studies 
have demonstrated that intravitreal injection of 
bevacizumab1-6, triamcinolone1,2,7,8 and sustained 
release dexamethasone9 have a beneficial effect 
on refractory DME in terms of central macular 
thickness (CMT) reduction and visual acuity (VA) 
improvement; but satisfying visual and anatomical 
results may not always be achieved. Anti vascular 
endothelial growth factor (VEGF) therapy requires 
monthly injection of the antibodies for a long time 
to maintain vision, which poses a cumulative risk 
of ocular and systemic complications. Therefore, 
new treatment modalities and intravitreal drugs 
with more efficacy and long term effects seem 
to be necessary.
Improved understanding of the 
pathophysiology of diabetic retinopathy has 
facilitated the development of new drugs for 
treatment of DME in cases refractory to current Fasudil for Diabetic Macular Edema; Nourinia et al
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therapies. In addition to the previously known 
high VEGF levels, increased activity of the Rho/
Rock pathway has recently been demonstrated 
in diabetic patients. This pathway promotes 
leukocyte adhesion to the retinal vascular 
endothelium by increasing intercellular 
adhesion molecule 1 (ICAM-1) expression and 
stimulating myosin regulatory light chain (MLC) 
phosphorylation.10,11 Furthermore, increased 
activity of the Rho/Rock pathway inactivates 
endothelial nitric oxide synthase (eNOS), thereby 
reducing physiological levels of nitric oxide 
(NO), a potent vasodilator and anti-apoptotic 
factor. Therefore, retinal endothelial cell damage 
occurs as a result of leukocyte adhesion and 
decreased eNOS activity.12 Experimental 
studies have demonstrated that Fasudil (Asahi 
Kasei Pharma Corporation, Tokyo, Japan) as a 
potent ROCK inhibitor can suppress leukocyte 
adhesion and prevent neutrophil-induced retinal 
endothelial cell damage.13
In this prospective interventional case 
series, we evaluated the anatomical and visual 
outcomes of combined injection of intravitreal 
bevacizumab (IVB) and Fasudil in patients with 
refractory DME. 
METHODS
Fifteen eyes of 15 patients with the following 
criteria were included: presence of type 2 diabetes 
mellitus and DME with no CMT reduction or VA 
improvement after one or more IVB injections, 
BCVA ≤ 20/40 and severe DME defined as CMT 
more than 320 µm associated with large cystoid 
changes and/or neurosensory detachment. 
Exclusion criteria were active proliferative 
diabetic retinopathy, monocularity or VA of 
fellow eye <20/40, other macular disorders, 
intravitreal bevacizumab injection within the 
past 3 months, and ocular surgery over the past 
6 months.
All patients received IVB (1.25 mg/0.05 ml) 
and intravitreal Fasudil injection (0.025 mg/0.05 
ml) using two separate syringes and at two 
separate sites followed by anterior chamber 
paracentesis. Best-corrected visual acuity 
(BCVA) was measured and optical coherence 
tomography (OCT) images were obtained before 
and one month after the injections. 
The study was approved by the Ethics 
Committee of the Ophthalmic Research Center 
and written informed consent was obtained from 
all participants. 
RESULTS
Mean age of the patients was 64.6±7.3 (range, 49-
79) years and the mean number of previous IVB 
injections was 2.8. Mean BCVA was 0.84±0.35 
logMAR before intervention improving to 
0.49±0.29 logMAR four weeks after treatment 
Figure 1. Optical coherence tomography images of three patients (A, B and C) show significant reduction of central 
macular thickness (CMT) one month after intravitreal injection of bevacizumab and Fasudil. CMT before treatment 
(top images) was 559, 516 and 455 µm decreasing to 281, 344 and 330 µm one month after treatment (lower images) in 
patients A, B and C, respectively.Fasudil for Diabetic Macular Edema; Nourinia et al
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(P=0.003). Mean pre-injection CMT was 448±123 
µm decreasing to 347±76 µm four weeks after 
treatment (P=0.001) (Table 1 & Figure 1). No 
adverse effects such as intraocular inflammation, 
vascular accident and IOP rise were observed 
following intravitreal injection of Fasudil and 
bevacizumab. 
DISCUSSION
The short term results of this case series showed 
that in DME refractory to IVB, combined 
intravitreal bevacizumab and Fasudil injection 
resulted in structural (CMT reduction) and 
functional (BCVA) improvement. These 
results are comparable or superior to other 
studies reporting intravitreal injection of 
bevacizumab, triamcinolone and sustained 
release dexamethasone in patients with 
refractory DME.1-9 
Multiple factors contribute to hyper-
permeability of retinal vessel walls in diabetic 
patients. Rho/ROCK pathway activity in 
diabetic patients leads to adhesion of leukocytes 
to vascular endothelial cells, damaging them by 
affecting the expression of adhesion molecules 
including ICAM-1 and integrin.10,11 Endothelial 
cell damage results in hyper-permeability 
of  vessel walls, leading to macular edema. 
Fasudil is a potent and selective ROCK 
inhibitor. In vivo studies have demonstrated 
that intravitreal injection of Fasudil effectively 
suppresses increased ICAM-1 expression and 
retinal leukocyte adhesion in diabetic animals. 
Moreover, in a recent study, Fasudil effectively 
suppressed endothelial damage even when 
leukocytes firmly adhered to the endothelium.13 
This suggests that Fasudil may protect vascular 
endothelial cells directly. This effect may be due 
to reversion of eNOS activity, in addition to 
inhibition of leukocyte adhesion. 
We used 0.025 mg Fasudil intravitreally to 
achieve an intraocular concentration of 10µM/L.14 
Previous animal studies have not shown any 
obvious electrophysiological or morphological 
toxicity up to a maximum concentration of 100 
µM/L.15 ERG findings in our previous study14 
and comprehensive ocular examinations in the 
current study did not show any toxic effect 
associated with intravitreal Fasudil injection.
The results of this study and our previous 
report on a smaller number of cases14 
No
Age
(years)
Sex Eye Hx MPC Hx IVB
BCVA Snellen (logMAR) CMT (µm)
Baseline
4 wk after 
treatment
Change (%) Baseline
4 wk after 
treatment
Change (%)
1 63 M OD 1 2 1/10 (1) 3/10 (0.52) 48 400 371 7
2 79 M OS 1 3* 1/10 (1) 3/10 (0.52) 48 367 344 6
3 59 M OS 1 2 4/10 (0.4) 8/10 (0.1) 75 372 291 22
4 64 F OS 1 3 CF 3 (1.3) CF 3 (1.3) 0 493 302 39
5 65 M OS 1 7 CF 2 (1.5) 3/10 (0.52) 65 439 323 26
6 64 M OD 1 2 1/10 (1) 6/10 (0.22) 78 516 344 33
7 61 M OS 1 3 1/10 (1) 2/10 (0.7) 30 392 344 12
8 76 M OS 1 3 3/10 (0.52) 7/10 (0.15) 71 358 330 8
9 49 M OS 1 4 2/10 (0.7) 4/10 (0.4) 43 570 441 23
10 67 M OS 1 4 4/10 (0.4) 4/10 (0.4) 0 324 327 -1
11 67 M OS 1 1 3/10 (0.52) 3/10 (0.52) 0 559 281 50
12 70 M OD 1 1 3/10 (0.52) 3/10 (0.52) 0 784 581 26
13 63 F OS 1 2 CF 4 (1.2) 2/10 (0.7) 42 455 330 27
14 56 F OS 1 1 3/10 (0.52) 5/10 (0.3) 42 341 326 4
15 66 F OD 1 5 1/10 (1) 3/10 (0.52) 48 344 275 20
Mean ± SD 0.84 ± 0.35 0.49 ± 0.29 39 ± 28 448 ± 123 347 ± 76 20 ± 14
P-value for the change (Wilcoxon signed rank test) 0.003 0.001
Table 1. Number of previous intravitreal bevacizumab injections; best-corrected visual acuity and central macular 
thickness at baseline and 4 weeks after combined intravitreal injection of bevacizumab and Fasudil
M, male; F, female; OD, right eye; OS, left eye; Hx, history of previous treatment; MPC, macular photocoagulation; IVB, intravitreal 
bevacizumab; BCVA, best-corrected visual acuity; CMT, central macular thickness; SD, standard deviation 
*Also treated once by IVTFasudil for Diabetic Macular Edema; Nourinia et al
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demonstrate a possible beneficial effect from 
intravitreal injection of Fasudil in combination 
with IVB in patients with DME unresponsive to 
monotherapy with IVB. This combination may 
reduce retinal vessel hyper-permeability via 
simultaneous inhibition of VEGF activity and 
endothelial cell damage more effectively than 
intravitreal injection of an anti-VEGF alone. 
In summary, combined intravitreal injection 
of bevacizumab and Fasudil seems to entail 
a beneficial effect in terms of structural and 
functional outcomes in eyes with severe DME 
resistant  to current therapeutic modalities. 
Studies with larger sample size and longer 
follow-up are required to establish the use of 
Fasudil for DME. 
Conflicts of Interest
None.
REFERENCES
1.  Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh 
B, Tabatabaei A, Azarmina M, et al. Intravitreal 
bevacizumab with or without triamcinolone for 
refractory diabetic macular edema; a placebo – 
controlled, randomized clinical trial. Graefes Arch 
Clin Exp Ophthalmol 2008;246:483-489.
2.  Shoeibi N, Ahmadieh H, Entezari M, Yaseri 
M. Intravitreal bevacizumab with or without 
triamcinolone for refractory diabetic macular 
edema: long-term results of a clinical trial. J 
Ophthalmic Vis Res. 2013;8:99-106.
3.  Rajendram R, Fraser-Bell S, Kaines A, Michaelides 
M, Hamilton RD, Esposti SD, et al. A 2–year 
prospective randomized controlled trial of 
intravitreal bevacizumab or laser therapy (BOLT) 
in the management of diabetic macular edema: 24- 
month data: report 3. Arch Ophthalmol 2012;130:972-
979.
4.  Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief 
SL, Grand MG. Intravitreal bevacizumab for the 
treatment of refractory diabetic macular edema. 
Ophthalmic Surg Lasers Imaging 2010;41:323-329.
5.  Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss 
R, Ulbig M, et al. Long- term effect of intravitreal 
bevacizumab (avastin) in patients with chronic 
diffuse diabetic macular edema. Retina 2008;28:1053-
1060.
6.  Gulkilik G, Taskapili M, Kocabora S, Muftuoglu 
G, Demirci G. Intravitreal bevacizumab for 
persistent macular edema with proliferative diabetic 
retinopathy. Int Ophthalmol 2010;30:697- 702.
7.  Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali 
H, Zhu M. Intravitreal triamcinolone for refractory 
diabetic macular edema: two-year results of a 
double-masked, placebo-controlled, randomized 
clinical trial. Ophthalmology 2006;113:1533-1538. 
8.  Gillies MC, Simpson JM, Gaston C, Hunt G, Ali 
H, Zhu M, et al. Five-year results of a randomized 
trial with open-label extension of triamcinolone 
acetonide for refractory diabetic macular edema. 
Ophthalmology 2009;116:2182-2187. 
9.  Haller JA, Kuppermann BD, Blumenkranz MS, 
Williams GA, Weinberg DV, Chou C, et al. 
Randomized controlled trial of an intravitreous 
dexamethasone drug delivery system in patients 
with diabetic macular edema. Arch Ophthalmol 
2010;128:289-296.
10. Lee H, Lin CI, Liao JJ, Lee YW, Yang HY, Lee 
CY, et al. Lysophospholipids increase ICAM-1 
expression in HUVEC through a Gi- and NF-kappa-
B-dependent mechanism. Am J Physiol Cell Physiol 
2004;287:1657-1666.
11. Kimura K, Ito M, Amano M, Chihara K, Fukata 
Y, Nakafuku M, et al. Regulation of myosin 
phosphatase by Rho and Rho-associated kinase 
(Rho-Kinase). Science 1996;273:245-248.
12. Ming XF, Viswambharan H, Barandier C, Ruffieux 
J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho 
kinase negatively regulates endothelial nitric oxide 
synthase phosphorylation through the inhibition of 
protein kinase B/Akt in human endothelial cells. 
Mol Cell Biol 2002;22:8467-8477.
13. Arita R, Hata Y, Nakao S, Kita T, Miura M, 
Kawahara S, et al. Rho kinase inhibition by fasudil 
ameliorates diabetes-induced microvascular 
damage. Diabetes 2009;58:215-226.
14. Ahmadieh H, Nourinia R, Hafezi-Moghadam A. 
Intravitreal fasudil combined with bevacizumab 
for persistent diabetic macular edema: a novel 
treatment. JAMA Ophthalmol 2013;131:923-924.
15. Kita T, Hata Y, Arita R, Kawahara S, Miura M, 
Nakao S, et al. Role of TGF-β in proliferative 
vitreoretinal diseases and ROCK as a therapeutic 
target. Proc Natl Acad Sci USA 2008;105:17504-17509.